Taiwan Liposome Co. Ltd. and Ablynx N.V. are investigating whether combining their technologies can yield next-generation antibody-drug conjugates that deliver more molecules more precisely than existing ADC technologies.

TLC manufactures liposomal formulations of the generic drugs amphotericin B, doxorubicin and alprostadil. While liposomes preferentially accumulate at tumor sites due to abnormal vasculature, the biotech is seeking to actively target liposomes to tumors by adding targeting ligands to the surface.